Affiliation:
1. Department of Otolaryngology, Head and Neck Surgery The First Affiliated Hospital of Anhui Medical University Hefei Anhui China
2. Department of Otolaryngology, Head and Neck Surgery The Affiliated Bozhou Hospital of Anhui Medical University Bozhou Anhui China
3. Department of Clinical Medicine Anhui Medical University Hefei Anhui China
4. Department of Oncology The First Affiliated Hospital of Anhui Medical University Hefei Anhui China
5. Department of Epidemiology and Biostatistics, School of Public Health Anhui Medical University Hefei Anhui China
Abstract
ObjectiveThe purpose of this study was to assess the diagnostic performance of narrow‐band imaging (NBI) in monitoring patients with head and neck carcinomas posttreatment and to compare it with that of white light endoscopy (WLE).Data SourcesPubMed, Embase, Web of Science (WOS), Cochrane Library, China Biology Medicine disc (CBM disc), China National Knowledge Internet (CNKI), Wanfang Data, China Science and Technology Journal Database (CSTJ), Chinese Clinical Trial Register.Review MethodsUsing the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA), literature published before July 2024 was searched. Patients who underwent surgery, radiotherapy (RT), or chemo‐RT for head and neck carcinomas with posttreatment follow‐up using NBI were analyzed. The main outcomes were sensitivity, specificity, and diagnostic odds ratio (DOR) for NBI and WLE in posttreatment follow‐up.ResultsThe sensitivity, specificity, and DOR for NBI and WLE in posttreatment follow‐up for head and neck carcinomas were 95% (95% confidence interval [CI]: 88%–98%), 96% (95% CI: 92%–98%), 433 (95% CI: 120–1560) and 72% (95% CI: 49%–87%), 72% (95% CI: 4%–99%), 7 (95% CI: 0–191). Additionally, the area under the curve (AUC) values for NBI and WLE were 0.99 (95% CI: 0.97–0.99) and 0.75 (95% CI: 0.71–0.79), respectively. The number of lesions and patients, treatment modality, follow‐up time, disease, and endoscopic system might be sources of heterogeneity.ConclusionCompared to WLE, NBI demonstrated superior diagnostic performance in follow‐up patients with head and neck carcinoma posttreatment. NBI offers technical support and a clinical foundation for early detection of head and neck carcinoma recurrence.Level of EvidenceNA Laryngoscope, 2024